Misplaced Pages

Draft:Dazadrol: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 15:35, 17 December 2024 editRA0808 (talk | contribs)Extended confirmed users, New page reviewers, Pending changes reviewers, Rollbackers100,211 editsm RA0808 moved page Dazadrol to Draft:Dazadrol: Article appears to be incomplete, moving to draft space← Previous edit Latest revision as of 22:09, 19 December 2024 edit undoBearcat (talk | contribs)Autopatrolled, Administrators1,564,929 edits WP:DRAFTNOCAT 
(5 intermediate revisions by 2 users not shown)
Line 58: Line 58:
| StdInChIKey = DITYEPYMBCHKLF-UHFFFAOYSA-N | StdInChIKey = DITYEPYMBCHKLF-UHFFFAOYSA-N
}} }}
Antidepressant.<ref> Schmitt H, Petillot N. Propriétés pharmacologiques d'un nouvel antidépresseur potentiel: le ((p-chlorophényl)-2-(pyridyl)-hydroxyméthyl) imidazoline (SCH 12.650 . Therapie. 1971 Jul-Aug;26(4):805-21. French. PMID: 5119131.</ref> Dazadrol is an antidepressant first quoted in the literature in 1971.<ref> Schmitt H, Petillot N. Propriétés pharmacologiques d'un nouvel antidépresseur potentiel: le ((p-chlorophényl)-2-(pyridyl)-hydroxyméthyl) imidazoline (SCH 12.650 . Therapie. 1971 Jul-Aug;26(4):805-21. French. PMID: 5119131.</ref>


Noradrenaline reuptake inhibitor and gastric acid secretion inhibitor.<ref> Lippmann, W. (1970). "Blockade of noradrenaline uptake and inhibition of gastric acid secretion by 2- imidazoline maleate (Sch-12650)". Journal of Pharmacy and Pharmacology. 22 (5): 387–388. doi:10.1111/j.2042-7158.1970.tb08548.x.</ref> It's mode of action is stated to be ] and it is a ].<ref> Lippmann, W. (1970). "Blockade of noradrenaline uptake and inhibition of gastric acid secretion by 2- imidazoline maleate (Sch-12650)". Journal of Pharmacy and Pharmacology. 22 (5): 387–388. doi:10.1111/j.2042-7158.1970.tb08548.x.</ref>


==Synthesis== ==Synthesis==
Line 66: Line 66:
</ref> #3 substance:<ref>Lewis A. Walter, US4081544 (1978 to Merck Sharp and Dohme Corp).</ref><ref>Lewis A. Walter, US3932431 (1976 to Merck Sharp and Dohme Corp).</ref> </ref> #3 substance:<ref>Lewis A. Walter, US4081544 (1978 to Merck Sharp and Dohme Corp).</ref><ref>Lewis A. Walter, US3932431 (1976 to Merck Sharp and Dohme Corp).</ref>
] ]
The reaction between p-chlorophenylacetonitrile (1) and ] (2) in the presence of a suitable base gives (3). Reaction with ethylenediamine forms the imidazoline ring giving (4). Air oxidation then affords the tertiary carbinol by attack at the highly activated, multiply benzylic carbon. There is thus obtained the antidepressant dazadrol (5). The reaction between p-chlorophenylacetonitrile (1) and ] (2) in the presence of a suitable base gives (3). Reaction with ethylenediamine forms the imidazoline ring giving (4). Air oxidation then affords the tertiary carbinol by attack at the highly activated benzylic carbon giving dazadrol (5).
==See also==
*]
== References == == References ==
{{reflist}} {{reflist}}
Line 72: Line 74:
{{Antidepressants}} {{Antidepressants}}
{{Monoamine reuptake inhibitors}} {{Monoamine reuptake inhibitors}}

]
{{Drafts moved from mainspace|date=December 2024}}
]
]

Latest revision as of 22:09, 19 December 2024

Dazadrol
Clinical data
Other namesSch 12650
Identifiers
IUPAC name
  • (4-chlorophenyl)-(4,5-dihydro-1H-imidazol-2-yl)-pyridin-2-ylmethanol
CAS Number
ChemSpider
Chemical and physical data
FormulaC15H14ClN3O
Molar mass287.75 g·mol
3D model (JSmol)
SMILES
  • C1CN=C(N1)C(C2=CC=C(C=C2)Cl)(C3=CC=CC=N3)O
InChI
  • InChI=1S/C15H14ClN3O/c16-12-6-4-11(5-7-12)15(20,14-18-9-10-19-14)13-3-1-2-8-17-13/h1-8,20H,9-10H2,(H,18,19)
  • Key:DITYEPYMBCHKLF-UHFFFAOYSA-N

Dazadrol is an antidepressant first quoted in the literature in 1971.

It's mode of action is stated to be Noradrenaline reuptake inhibitor and it is a gastric acid secretion inhibitor.

Synthesis

Patent (Ex 12): #3 substance:

The reaction between p-chlorophenylacetonitrile (1) and 2-bromopyridine (2) in the presence of a suitable base gives (3). Reaction with ethylenediamine forms the imidazoline ring giving PC20361737 (4). Air oxidation then affords the tertiary carbinol by attack at the highly activated benzylic carbon giving dazadrol (5).

See also

References

  1. Schmitt H, Petillot N. Propriétés pharmacologiques d'un nouvel antidépresseur potentiel: le ((p-chlorophényl)-2-(pyridyl)-hydroxyméthyl) imidazoline (SCH 12.650 . Therapie. 1971 Jul-Aug;26(4):805-21. French. PMID: 5119131.
  2. Lippmann, W. (1970). "Blockade of noradrenaline uptake and inhibition of gastric acid secretion by 2- imidazoline maleate (Sch-12650)". Journal of Pharmacy and Pharmacology. 22 (5): 387–388. doi:10.1111/j.2042-7158.1970.tb08548.x.
  3. Walter Lewis A, DE1905353A1 (1969 to Scherico Ltd).
  4. Lewis A. Walter, US4081544 (1978 to Merck Sharp and Dohme Corp).
  5. Lewis A. Walter, US3932431 (1976 to Merck Sharp and Dohme Corp).
Antidepressants (N06A)
Specific reuptake inhibitors and/or receptor modulators
SSRIsTooltip Selective serotonin reuptake inhibitors
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors
NRIsTooltip Norepinephrine reuptake inhibitors
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants
SARIsTooltip Serotonin antagonist and reuptake inhibitors
SMSTooltip Serotonin modulator and stimulators
Others
Tricyclic and tetracyclic antidepressants
TCAsTooltip Tricyclic antidepressants
TeCAsTooltip Tetracyclic antidepressants
Others
Monoamine oxidase inhibitors
Non-selective
MAOATooltip Monoamine oxidase A-selective
MAOBTooltip Monoamine oxidase B-selective
Adjunctive therapies
Miscellaneous
Monoamine reuptake inhibitors
DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors)
NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors)
SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors)
VMATsTooltip Vesicular monoamine transporters
Others
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins